Research sheds light on what causes severe inflammatory bowel disease.

Published Date: 26 Apr 2023

Researchers from Cedars-Sinai have discovered a genetic variation that raises the risk of perianal Crohn's disease, the most crippling form of the condition, in susceptible individuals.

Read Full News

Latest News

AI Beats Conventional Endoscopy in Neoplasm Detection

AI-assisted esophagogastroduodenoscopy is more effective than the conventional procedure in detecting upper GI neoplasms, particularly for lesions measuring ≤ 10 mm.

Global Study Supports Meat-Free Diets for Cancer Prevention

Observational data on more than 1.8 million people did yield surprises when it came to colorectal and esophageal cancers.

Healthy Midlife Diet Tied to Lower Risk of Cognitive Decline

Greater adherence to the DASH diet and other healthy eating patterns — especially in midlife — is linked to lower risk of cognitive decline later in life, three major US studies show.

CDC Vaccine Advisors to Consider COVID-19 Vaccine Injuries, Long COVID

The U.S. CDC's vaccine advisory committee will discuss and may vote on recommendations ⁠for issues including COVID-19 vaccine injuries and long COVID at its scheduled...

Risankizumab Effective in Crohn's, Real-World Data Show

Risankizumab is effective in inducing clinical and endoscopic remission and is generally well tolerated in patients with Crohn's disease, a real-world study shows.

Rifabutin Regimen Matches Bismuth Regimen in H pylori Rescue

Rifabutin-based triple regimen is noninferior to classical bismuth quadruple regimen as rescue treatment for Helicobacter pylori infection.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Latest News

AI-assisted esophagogastroduodenoscopy is more effective than the conventional procedure in detecting upper GI neoplasms, particularly for lesions measuring ≤ 10 mm.

Observational data on more than 1.8 million people did yield surprises when it came to colorectal and esophageal cancers.

Greater adherence to the DASH diet and other healthy eating patterns — especially in midlife — is linked to lower risk of cognitive decline later in life, three major US studies show.

The U.S. CDC's vaccine advisory committee will discuss and may vote on recommendations ⁠for issues including COVID-19 vaccine injuries and long COVID at its scheduled...

Risankizumab is effective in inducing clinical and endoscopic remission and is generally well tolerated in patients with Crohn's disease, a real-world study shows.

Rifabutin-based triple regimen is noninferior to classical bismuth quadruple regimen as rescue treatment for Helicobacter pylori infection.

News All Time

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Rimegepant Linked to Increased Rectal Compliance, Reduced Rectal Sensation in IBS, With Ayah Matar, MD Ayah Matar, MD

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

Q4 2025 Recap: Gastroenterology News and Updates

Q4 2025 Recap: Gastroenterology News and Updates

5 Gastroenterology Headlines You Missed in December 2025

5 Gastroenterology Headlines You Missed in December 2025

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Gastroenterology in 2025: Year in Review

Gastroenterology in 2025: Year in Review

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

Recommended News For You

For treatment, the majority of cancer patients choose complementary therapies.

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.

Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

healthy despite having advanced cancer.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

Recommended Articles For You

Angina Haemorrhagica Bullosa: What You Need to Know 

Exploring New Treatment Strategies for Mantle Cell Lymphoma 

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways 

Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.

2.

3D virtual staining technology enables non-invasive observation of cancer tissue

3.

enhancing survivors of brain tumors' quality of life.

4.

Why are so many young adults getting cancer?

5.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

1.

Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis 

2.

Exploring the Impact of Adrenal Myelolipoma on the Human Body

3.

Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis

4.

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing

5.

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

2.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot